Sino Biopharmaceutical Limited (SBHMY)
USD 9.48
(-7.96%)
USD 9.48
(-7.96%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.84 Billion CNY | -27.38% |
| 2022 | 2.54 Billion CNY | -82.59% |
| 2021 | 14.6 Billion CNY | 427.17% |
| 2020 | 2.77 Billion CNY | 0.35% |
| 2019 | 2.76 Billion CNY | -69.47% |
| 2018 | 9.04 Billion CNY | 316.7% |
| 2017 | 2.17 Billion CNY | 32.59% |
| 2016 | 1.63 Billion CNY | 9.93% |
| 2015 | 1.48 Billion CNY | 23.09% |
| 2014 | 1.21 Billion CNY | 49.36% |
| 2013 | 810.13 Million CNY | 12.95% |
| 2012 | 717.23 Million CNY | 91.49% |
| 2011 | 374.55 Million CNY | -22.47% |
| 2010 | 483.12 Million CNY | 38.23% |
| 2009 | 349.5 Million CNY | 33.37% |
| 2008 | 262.05 Million CNY | 24.68% |
| 2007 | 210.17 Million CNY | 48.48% |
| 2006 | 141.55 Million CNY | -91.13% |
| 2005 | 1.59 Billion CNY | 788.94% |
| 2004 | 179.5 Million CNY | 106.28% |
| 2003 | 87.01 Million CNY | 42.93% |
| 2002 | 60.88 Million CNY | -7.07% |
| 2001 | 65.51 Million CNY | 37.31% |
| 2000 | 47.71 Million CNY | 25.08% |
| 1999 | 38.14 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 181.2 Million USD | 0.0% |
| 2023 Q1 | 629.39 Million USD | 605.97% |
| 2023 FY | 1.84 Billion CNY | -27.38% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q4 | 148.27 Million USD | 0.0% |
| 2023 Q2 | 181.61 Million USD | -71.14% |
| 2022 Q4 | 89.15 Million USD | -71.36% |
| 2022 Q1 | 960.51 Million CNY | -68.65% |
| 2022 Q2 | 960.51 Million CNY | 0.0% |
| 2022 FY | 2.54 Billion CNY | -82.59% |
| 2022 Q3 | 311.26 Million USD | -67.59% |
| 2021 Q2 | 6.56 Billion CNY | 243.19% |
| 2021 Q4 | 3.06 Billion CNY | 0.0% |
| 2021 Q3 | 3.06 Billion CNY | -53.34% |
| 2021 FY | 14.6 Billion CNY | 427.17% |
| 2021 Q1 | 1.91 Billion CNY | 107.86% |
| 2020 Q3 | 637.41 Million CNY | 81.57% |
| 2020 FY | 2.77 Billion CNY | 0.35% |
| 2020 Q1 | 875.78 Million CNY | 94.07% |
| 2020 Q2 | 351.05 Million CNY | -59.92% |
| 2020 Q4 | 920.58 Million CNY | 44.42% |
| 2019 Q1 | 856.7 Million CNY | -87.48% |
| 2019 FY | 2.76 Billion CNY | -69.47% |
| 2019 Q4 | 451.27 Million CNY | -44.37% |
| 2019 Q3 | 811.16 Million CNY | 38.04% |
| 2019 Q2 | 587.64 Million CNY | -31.41% |
| 2018 FY | 9.04 Billion CNY | 316.7% |
| 2018 Q1 | 771.1 Million CNY | 110.69% |
| 2018 Q2 | 594.56 Million CNY | -22.89% |
| 2018 Q3 | 835.58 Million CNY | 40.54% |
| 2018 Q4 | 6.84 Billion CNY | 719.19% |
| 2017 Q4 | 365.99 Million CNY | -48.04% |
| 2017 Q3 | 704.37 Million CNY | 35.05% |
| 2017 Q2 | 521.57 Million CNY | -9.92% |
| 2017 Q1 | 579.01 Million CNY | 55.26% |
| 2017 FY | 2.17 Billion CNY | 32.59% |
| 2016 Q3 | 477.18 Million CNY | 12.87% |
| 2016 Q1 | 427.55 Million CNY | 22.91% |
| 2016 Q4 | 372.92 Million CNY | -21.85% |
| 2016 FY | 1.63 Billion CNY | 9.93% |
| 2016 Q2 | 422.77 Million CNY | -1.12% |
| 2015 Q2 | 423.4 Million CNY | 32.22% |
| 2015 FY | 1.48 Billion CNY | 23.09% |
| 2015 Q1 | 320.22 Million CNY | 9.15% |
| 2015 Q4 | 347.85 Million CNY | -12.59% |
| 2015 Q3 | 397.95 Million CNY | -6.01% |
| 2014 Q4 | 293.37 Million CNY | -28.29% |
| 2014 Q2 | 240.5 Million CNY | -9.94% |
| 2014 Q1 | 267.05 Million CNY | 79.24% |
| 2014 FY | 1.21 Billion CNY | 49.36% |
| 2014 Q3 | 409.09 Million CNY | 70.1% |
| 2013 Q1 | 212 Million CNY | 1.44% |
| 2013 Q2 | 172.55 Million CNY | -18.61% |
| 2013 Q3 | 276.57 Million CNY | 60.28% |
| 2013 Q4 | 148.99 Million CNY | -46.13% |
| 2013 FY | 810.13 Million CNY | 12.95% |
| 2012 Q1 | 165.72 Million CNY | 16.45% |
| 2012 Q4 | 208.98 Million CNY | -7.11% |
| 2012 Q3 | 224.97 Million CNY | 91.4% |
| 2012 Q2 | 117.53 Million CNY | -29.08% |
| 2012 FY | 717.23 Million CNY | 91.49% |
| 2011 Q2 | 96.74 Million CNY | 11.02% |
| 2011 Q1 | 87.14 Million CNY | 0.0% |
| 2011 FY | 374.55 Million CNY | -22.47% |
| 2011 Q3 | 48.35 Million CNY | -50.02% |
| 2011 Q4 | 142.31 Million CNY | 194.32% |
| 2010 Q2 | 88.85 Million CNY | 11.94% |
| 2010 Q1 | 79.37 Million CNY | 0.0% |
| 2010 FY | 483.12 Million CNY | 38.23% |
| 2009 FY | 349.5 Million CNY | 33.37% |
| 2008 FY | 262.05 Million CNY | 24.68% |
| 2007 FY | 210.17 Million CNY | 48.48% |
| 2006 FY | 141.55 Million CNY | -91.13% |
| 2005 FY | 1.59 Billion CNY | 788.94% |
| 2004 FY | 179.5 Million CNY | 106.28% |
| 2003 FY | 87.01 Million CNY | 42.93% |
| 2002 FY | 60.88 Million CNY | -7.07% |
| 2001 FY | 65.51 Million CNY | 37.31% |
| 2000 FY | 47.71 Million CNY | 25.08% |
| 1999 FY | 38.14 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.17 Million USD | 58344.278% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 49886.078% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 77684.244% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -3386.627% |
| GB Sciences, Inc. | -1.36 Million USD | 135754.785% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 61140.899% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 809815.641% |
| Skye Bioscience, Inc. | -37.64 Million USD | 5006.868% |
| Zenith Capital Corp. | -10.59 Million USD | 17532.805% |
| Agentix Corp. | -1.37 Million USD | 134517.495% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 26553.149% |
| Biomind Labs Inc. | -1.21 Million USD | 152216.536% |
| ContraFect Corporation | -65.15 Million USD | 2935.142% |
| CSL Limited | 2.64 Billion USD | 30.084% |
| CytoDyn Inc. | -49.84 Million USD | 3806.146% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 94863.676% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 292187.216% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 3050.814% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 444690.461% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 101563.971% |
| Regen BioPharma, Inc. | 1.02 Million USD | -180375.385% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -2736.016% |
| SQZ Biotechnologies Company | -79.46 Million USD | 2424.549% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 85230.799% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 2564.122% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 63963.36% |
| Mesoblast Limited | -87.95 Million USD | 2200.118% |
| Marizyme, Inc. | -65.34 Million USD | 2926.729% |
| Genus plc | 7.9 Million USD | -23282.025% |
| Pharming Group N.V. | -10.54 Million USD | 17612.135% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 20986.251% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 107030.716% |
| IMV Inc. | -36.48 Million USD | 5162.751% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 23018.77% |
| MultiCell Technologies, Inc. | -380.07 USD | 486010571.755% |
| ONE Bio Corp. | 8.67 Million USD | -21189.185% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 3673.435% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 49582.454% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 59652.487% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 23472.874% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 12334368.162% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 11738.387% |
| Alpha Cognition Inc. | -13.77 Million USD | 13512.024% |
| Enzolytics Inc. | -2.17 Million USD | 84956.342% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 726.05% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -1884777.551% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -26575.643% |
| Genscript Biotech Corporation | -95.47 Million USD | 2034.686% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 28189.246% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 675727.83% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 44653.992% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 3056290.201% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 92223.394% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 17059.456% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 37905.079% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 49405.217% |
| Helix BioMedix, Inc. | -1.05 Million USD | 175012.907% |
| EV Biologics, Inc. | -1.26 Million USD | 145876.216% |
| Q BioMed Inc. | -2.05 Million USD | 90114.439% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 48468.159% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 3192.788% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 21875.121% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 31853.475% |
| HST Global, Inc. | -146.21 Thousand USD | 1263474.598% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 138420.887% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 105366.157% |
| Halberd Corporation | -79.67 Thousand USD | 2318464.376% |
| Resverlogix Corp. | -3.61 Million USD | 51268.421% |
| Cell Source, Inc. | -5.32 Million USD | 34813.52% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 46593.412% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | 28900.77% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 7947694.871% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 38831.549% |
| Kadimastem Ltd | -3.3 Million USD | 55949.946% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 41679.414% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 418611.495% |
| LadRx Corporation | 400.44 Thousand USD | -461184.128% |
| Regen BioPharma, Inc. | 1.02 Million USD | -180375.385% |
| Affymax, Inc. | -14.42 Million USD | 12906.295% |
| Itoco Inc. | -1.86 Million USD | 98932.795% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 110775.854% |
| Mobile Lads Corp. | -2.26 Million USD | 81714.745% |
| International Stem Cell Corporation | -131 Thousand USD | 1410161.069% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -4.28 Million USD | 43258.391% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 2337326.222% |
| Qrons Inc. | -789.34 Thousand USD | 234113.685% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 196289.39% |
| SYBLEU INC | -180.3 Thousand USD | 1024580.877% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 88579.95% |
| Rebus Holdings, Inc. | -1.02 Million USD | 181196.078% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 114636.964% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 3403659.847% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 73103.94% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 3942.528% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 87478.43% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 236648.95% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 58407.449% |
| Neutra Corp. | -233.46 Thousand USD | 791302.107% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 9203.445% |
| PureTech Health plc | -65.69 Million USD | 2911.666% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 8785.852% |
| IXICO plc | -1.17 Million USD | 156906.452% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 18707.636% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 3333.406% |
| CSL Limited | 2.64 Billion USD | 30.084% |
| Cellectis S.A. | -103.17 Million USD | 1890.357% |